Dealing with the Emotions of Hepatitis C

Many people when they are first diagnosed with the Hepatitis C virus, also known as HCV, go through several emotional states. They are frequently angry, wanting to know why such a terrible illness has befallen them. Asking the question of what did they do to deserve such a fate. They are also scared, believing that their lives will never be the same.  They fear loneliness and an early demise. The questions they ask and the frustrations that they feel are very common initial reactions to this terrible news.  These are powerful emotions that need to be dealt with. Hepatitis C sufferers must take care of their emotional needs as well as work to keep their health.

One thing that can help is talking. It really is unhealthy to keep it all inside. Sometimes the best way to get the frustration and fear out is by seeing a councilor. One on one therapy is good for some people. There will be councilors who specialize in patients who are dealing with life threatening illnesses as a part of their normal practice. Others may prefer going to group therapy to have the opportunity to talk to others in similar circumstances. Most councilors have group sessions where people with similar needs will meet regularly to talk out their pain. These sessions can occur weekly or more often if the need is there. 

 There are also often meetings of groups of people, minus the councilor, who get together at community centers or storefronts to share their concerns and questions with others who have the same problems as they do.  There will likely be a group like this that meets to talk about living with Hepatitis. These meetings are also very useful as people with the same problems share ideas on treatments or on how to cope with family and friends now that they know they have the Hepatitis C virus.

Some people prefer anonymity when discussing private issues. They may therefore prefer to use chat rooms on the Internet.  There are so many of these available for any kind of illness one may have. People can talk to others from around the world; learn about what other people do to keep their spirits up. They can compare treatment options and see what success others have had using different drug programs. They may want to discuss other issues like diet or relationships to help understand better how to deal with their lives. Or maybe they are just feeling lonely and want to talk to people who may be able to understand their feelings better than those who may not be experiencing the same set of worries that they are.

Whichever route the person with Hepatitis C should choose, they should remember that they are not alone. Family will not desert them because of their illness and friends will not walk away. The people they have been close to before will also be there to listen and give comfort.  They can still be emotionally involved with people.

Hepatitis news on the Web

Liver specialists in Nevada are seeing an increase in patients since health officials in February announced an outbreak of hepatitis C cases linked to an endoscopy clinic.

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the Chinese hepatitis C virus drug market, dominated by conventional and pegylated interferons, will more than double by 2012 from $64 million in 2007 to $150 million in 2012.

Sept. 8 (Bloomberg) -- BioMerieux , the French maker of tests to diagnose infections such as HIV and hepatitis, said first-half profit rose 5.8 percent as higher sales in Latin America helped make up for a slowdown in the U.S.

Blood from donors and patients in Jersey is to be screened for HIV and Hepatitis C

The U.S. Food & Drug Administration (FDA) has approved the Roche COBAS(R) TaqMan(R) HBV Test, the first assay for quantitating Hepatitis B Virus DNA approved in the U.S. The test uses Roche's real-time PCR technology to quantify the amount of Hepatitis B virus DNA in a patient's blood.

Intercell AG (ICLL) announced the six months follow up data of its exploratory clinical phase-II study targeting treatment-naïve Hepatitis C genotype-1 patients.

A hepatitis E epidemic has killed 121 people in northern Uganda, where it erupted in October last year, a health ministry official said Thursday.

Pharmasset, Inc. announces the preliminary results of the fourth cohort of a 4-week Phase 1 proof-of-concept clinical trial evaluating R7128 1500mg twice daily in combination with the standard of care , Pegasys® plus Copegus® in 20 patients chronically infected with hepatitis C virus genotype 2 or 3 who had not achieved a Sustained Viral Response with prior SOC therapy.

Roche has announced that the FDA has approved its Cobas TaqMan HBV test, the first assay for quantitating hepatitis B virus DNA approved in the US.

The U.S. Food and Drug Administration (FDA) approved the first nucleic acid test for hepatitis B virus (HBV) that measures the amount of viral DNA (viral load) in a patient's blood. Assessing a patient's viral load provides health care professionals with a highly sensitive method for gauging the progress of antiviral therapy in patients with chronic HBV infections.